Last reviewed · How we verify

Irbesartan/HCTZ

Bristol-Myers Squibb · Phase 3 active Small molecule

Irbesartan/HCTZ is a Angiotensin II receptor blocker / Thiazide diuretic combination Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 3 development for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients at high risk. Also known as: Avapro.

Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.

Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume. Used for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients at high risk.

At a glance

Generic nameIrbesartan/HCTZ
Also known asAvapro
SponsorBristol-Myers Squibb
Drug classAngiotensin II receptor blocker / Thiazide diuretic combination
TargetAT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Irbesartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels, causing vasodilation and reduced vasoconstriction. Hydrochlorothiazide (HCTZ) is a thiazide diuretic that increases sodium and water excretion, reducing blood volume and cardiac output. Together, these complementary mechanisms provide additive antihypertensive effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Irbesartan/HCTZ

What is Irbesartan/HCTZ?

Irbesartan/HCTZ is a Angiotensin II receptor blocker / Thiazide diuretic combination drug developed by Bristol-Myers Squibb, indicated for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients at high risk.

How does Irbesartan/HCTZ work?

Irbesartan blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide acts as a thiazide diuretic to reduce fluid volume.

What is Irbesartan/HCTZ used for?

Irbesartan/HCTZ is indicated for Hypertension (high blood pressure), Reduction of cardiovascular events in hypertensive patients at high risk.

Who makes Irbesartan/HCTZ?

Irbesartan/HCTZ is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

Is Irbesartan/HCTZ also known as anything else?

Irbesartan/HCTZ is also known as Avapro.

What drug class is Irbesartan/HCTZ in?

Irbesartan/HCTZ belongs to the Angiotensin II receptor blocker / Thiazide diuretic combination class. See all Angiotensin II receptor blocker / Thiazide diuretic combination drugs at /class/angiotensin-ii-receptor-blocker-thiazide-diuretic-combination.

What development phase is Irbesartan/HCTZ in?

Irbesartan/HCTZ is in Phase 3.

What are the side effects of Irbesartan/HCTZ?

Common side effects of Irbesartan/HCTZ include Dizziness, Fatigue, Hyperkalemia (elevated potassium), Hypokalemia (low potassium), Hyperuricemia (elevated uric acid), Headache.

What does Irbesartan/HCTZ target?

Irbesartan/HCTZ targets AT1 receptor (angiotensin II type 1 receptor) / Sodium-chloride cotransporter and is a Angiotensin II receptor blocker / Thiazide diuretic combination.

Related